BRAIN FUEL METABOLISM, AGING AND ALZHEIMER’S DISEASE
By S. Cunnane, S. Nugent, M. Roy, A. Courchesne-Loyer, E. Croteau, S. Tremblay, Alex Castellano, F. Pifferi, C. Bocti, N. Paquet and 7 more. Nutrition (Burbank, Los Angeles County, Calif.), 2010
595 citations recorded by the source corpus.
Lower brain glucose metabolism is present before the onset of clinically-measurable cognitive decline in two groups of people at risk of Alzheimer’s disease (AD) - carriers of apoE4, and in those with a maternal family history of AD. Supported by emerging evidence from in vitro and animal studies, these reports suggest that brain hypometabolism may precede and contribute to the neuropathological cascade leading cognitive decline in AD. The reason for brain hypometabolism is unclear but may include defects in glucose transport at the blood-brain barrier, glycolysis, and/or mitochondrial function. Methodological issues presently preclude knowing with certainty whether or not aging in the absence of cognitive impairment is necessarily associated with lower brain glucose metabolism. Nevertheless, aging appears to increase the risk of deteriorating systemic control of glucose utilization which, in turn, may increase the risk of declining brain glucose uptake, at least in some regions. A contributing role of deteriorating glucose availability to or metabolism by the brain in AD does not exclude the opposite effect, i.e. that neurodegenerative processes in AD further decrease brain glucose metabolism because of reduced synaptic functionality and, hence, reduced energy needs, thereby completing a vicious cycle. Strategies to reduce the risk of AD by breaking this cycle should aim to – (i) improve insulin sensitivity by improving systemic glucose utilization, or (ii) bypass deteriorating brain glucose metabolism using approaches that safely induce mild, sustainable ketonemia.
Subfields: Health, Toxicology and Mutagenesis, Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/a0c4de08db6b42bf34d67fa76c145fbb2455d5bb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Physiology
Citations in the corpus
- Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, methodology): “Hence, FDG is accumulated in the neurons as the form of FDG-6-phosphate but without further metabolism to produce CO2 and H2O (Cunnane et al., 2011).”
- Inflammation as a central mechanism in Alzheimer's disease (2018, unknown): “[243] Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E,”
- Vascular dysfunction – the disregarded partner of Alzheimer’s disease (2019, unknown): “[71] Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, et al.”